$AMTD $BOXD $OBSV

Something’s cooking!

Here we go

Finally the time is here
November December and January are going to be crazy
Loading up ever week

This stock April 30 open 3.92 after rocked 255.88 marked cap close after marked close good luck every one

Sell if it breaks 4

Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

Not halted

Needs to hold above 4.19

Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

Alert a buy at 3.71 and if anyone is interested in learning dm me hari25sabari@gmail.com

Need to break 4.19

Seems like someone wants this company for cheap. As soon as they publish there results all of a sudden I start seeing a lot of not so good news. Something don’t smell right!!

Just hold strong...a good partner deal will send this to the moon. The company only have a market cap of $140 million. Approval of this drugs in Europe and the US will send this well over $1 billion in valuation.

$OBSV

MAKES NO SENSE

ObSeva Announces Positive Pilot Study Results From Linzagolix In Adenomyosis

Obseva SA (NASDAQ: OBSV) announced the publication in the journal Fertility and Sterility of a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis. The study showed the patient treated with linzagolix saw alleviation of symptoms such as cessation of bleeding, improvement in pelvic pain, resolution of anemia and shrinkage of uterus at week 12.

The symptoms continued to improve with the subsequent 12 weeks of treatment, and the effect lingered at eight weeks following the treatment.

Pending confirmation of the results in additional patients, ObsEva said it may pursue additional studies to support supplemental labeling for the treatment of adenomyosis in reproductive-age women.

ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of “Gonadotropin-releasing Hormone Antagonist (linzagolix): a New Therapy for Uterine Adenomyosis,” a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis.